Ruth Palmer Lab
Ruth Palmer Lab
News
People
Events
Publications
Contact
Funding
Diana Cervantes-Madrid
Latest
Repotrectinib (TPX-0005) effectively reduces growth of ALK-driven neuroblastoma cells
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas
Cite
×